---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-001271"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:56:44.607486+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Entera Bio posts 2022 net loss of $13.1M; cash runway into Q3 2024; FDA accepts Type D meeting for EB613

## Summary
- Net loss $13.1M ($0.45/share) vs $12.2M ($0.47/share) in 2021; revenues $134K, down from $571K.
- Cash and equivalents $12.3M; expects runway into Q3 2024, excluding Phase 3 EB613 funding.
- FDA accepted Type D meeting to confirm placebo-controlled Phase 3 design with TH BMD endpoint for EB613.
- EB613 (oral teriparatide) positioned as first daily tablet anabolic therapy for osteoporosis; Phase 2 results positive.
- New formulation EB612 (PTH(1-34) for hypoparathyroidism) entering Phase 1 PK study, targeting Phase 2 in 2024.

## SEC filing metadata
- accession: 0001178913-23-001271
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891323001271/0001178913-23-001271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891323001271/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-001271
- JSON: https://secwatch.observer/filing/0001178913-23-001271.json
- Plain text: https://secwatch.observer/filing/0001178913-23-001271.txt

## Key facts
- Earnings Releases
  Entera Bio Ltd. reported the fiscal year ended December 31, 2022 results: revenue $134,000, net income $13.1 million, EPS $0.45 per ordinary share (basic and diluted).
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $134,000
  - Net income: $13.1 million
  - EPS: $0.45 per ordinary share (basic and diluted)
  - Result: reported results
  source text: stated Miranda Toledano, Chief Executive Officer of Entera. Financial Results for the year Ended December 31, 2022 Revenues for the year ended December 31, 2022 and 2021 were $134,000 and $571,000, respectively, mainly attributable to research and development, or R&D services provided to Amgen and other third parties under material transfer agreements. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891323001271/0001178913-23-001271-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.